Docusign
Docusign's revenue rose 8.2% to $3.2 billion in fiscal 2026. Its operating margin was 9.3%, up from 6.7% a year earlier. Free cash flow was $1.1 billion, up 15.0%. It paid out $869 million in dividends and buybacks, 82% of free cash flow. The diluted share count fell 0.6%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2024 to 2026, earnings per share grew 102.8% a year and net income 104.4% a year, with the share count about the same.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Docusign yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Docusign's 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Docusign's fiscal 2026 free cash flow of $1.1B, net cash of $866M at January 31, 2026 and 209 million diluted shares, from its filings. The scenarios are fitted to Docusign: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 8.6% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 10%: 9% for a business of moderate risk (Application Software), plus 1 point for unsteady results (a loss in fiscal 2023); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $84.89
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Docusign's earnings per share of $1.64 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 51.8×, the middle of Docusign's own P/E today, its peers' median and its sector's median (Docusign's own P/E today) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 11%, 10% and 9%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $84.89
- Value at this multiple, against the last close
- —
- Docusign's P/E at the last close
- 51.8×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| OktaOKTA | $220.01 | $1.66 | 132.5× |
| HubSpotHUBS | $263.99 | $2.81 | 93.9× |
| DocusignDOCU | $84.89 | $1.64 | 51.8× |
Balance sheet
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | 803 | 1,032 | 1,046 | 964 | 866 |
| Debt incl. finance leases | 718 | 723 | 0 | 0 | 0 |
| Net debt (negative means net cash) | −84 | −309 | −1,046 | −964 | −866 |
| Net debt to EBITDA | −4.2x | — | −8.2x | −3.1x | −2.1x |
| Debt to equity | 2.6x | 1.2x | 0.0x | 0.0x | 0.0x |
| Interest coverage | −9.6x | −13.8x | 4.6x | 129.0x | 117.3x |
| Current ratio | 1.0x | 0.7x | 0.9x | 0.8x | 0.7x |
| Quick ratio | 1.0x | 0.7x | 0.9x | 0.8x | 0.7x |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Docusign shares on the open market, and 10 insiders sold $20.1 million, $17.0 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 17, 2026 | Robert ChatwaniPresident General Mgr, Growth | Sold plan | 14,676 | $69.41 | $1.0 million | Form 4 |
| Sep 16, 2026 | Mary Agnes WilderotterDirector | Sold plan | 1,096 | $70.60 | $77,378 | Form 4 |
| Sep 14, 2026 | Anna MarrsDirector | Sold plan | 548 | $67.00 | $36,716 | Form 4 |
| Sep 10, 2026 | Peter SolvikDirector | Sold | 46,000 | $65.24 | $3.0 million | Form 4 |
| Sep 10, 2026 | Teresa BriggsDirector | Sold plan | 548 | $64.60 | $35,401 | Form 4 |
| Sep 8, 2026 | Blake Jeffrey GraysonChief Financial Officer | Sold plan | 15,000 | $65.57 | $983,546 | Form 4 |
| Sep 4, 2026 | Blake Jeffrey GraysonChief Financial Officer | Sold plan | 30,000 | $70.00 | $2.1 million | Form 4 |
| Aug 28, 2026 | James A BeerDirector | Sold plan | 450 | $64.02 | $28,809 | Form 4 |
| Aug 7, 2026 | Blake Jeffrey GraysonChief Financial Officer | Sold plan | 15,000 | $60.00 | $900,000 | Form 4 |
| Jul 1, 2026 | Allan C. ThygesenPresident and CEO, Director | Sold plan | 26,250 | $46.02 | $1.2 million | Form 4 |
| Jul 1, 2026 | Blake Jeffrey GraysonChief Financial Officer | Sold plan | 15,000 | $45.55 | $683,226 | Form 4 |
| Jul 1, 2026 | James P ShaughnessyChief Legal Officer | Sold plan | 12,000 | $45.54 | $546,478 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY24 | FY25 | FY26 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Pass | Pass | Fail |
| Cash from operations exceeds net income | Pass | Fail | Pass |
| Debt fell relative to assets | Pass | Fail | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | Pass | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Fail |
| F-score | 7 of 9 | 4 of 9 | 5 of 9 |
| Accruals ratio | −30.3% | 1.4% | −20.8% |
Compare
Put Docusign side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Docusign | FY26 | 8.2% | 9.3% | 32.9% | 25.4% | −2.1x | 5 | |
| HubSpot | FY25 | 19.2% | 0.2% | 22.6% | — | — | — | Compare |
| Datadog | FY25 | 27.7% | −1.3% | 29.2% | — | −723.3x | 5 | Compare |
| NiCE | FY25 | 7.7% | 21.9% | 23.7% | 19.0% | −0.5x | 7 | Compare |
| Okta | FY26 | 11.8% | 5.1% | 30.0% | — | — | 8 | Compare |
10 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 382 | 518 | 701 | 974 | 1,453 | 2,107 | 2,516 | 2,762 | 2,977 | 3,220 |
| Revenue growth | — | 35.9% | 35.2% | 39.0% | 49.2% | 45.0% | 19.4% | 9.8% | 7.8% | 8.2% |
| Gross profit | 279 | 400 | 508 | 731 | 1,089 | 1,641 | 1,980 | 2,189 | 2,355 | 2,556 |
| Research and development | 90 | 92 | 186 | 186 | 272 | 393 | 481 | 540 | 588 | 665 |
| Operating income | −116 | −52 | −426 | −194 | −174 | −62 | −88 | 32 | 200 | 299 |
| Net income | −115 | −52 | −426 | −208 | −243 | −70 | −98 | 74 | 1,068 | 309 |
| Diluted EPS (US$) | −4.17 | −1.66 | −3.16 | −1.18 | −1.31 | −0.36 | −0.49 | 0.36 | 5.08 | 1.48 |
| Diluted shares (millions) | 28 | 32 | 135 | 177 | 186 | 197 | 201 | 209 | 210 | 209 |
| Cash flow | ||||||||||
| Cash from operations | −5 | 55 | 76 | 116 | 297 | 506 | 507 | 980 | 1,017 | 1,165 |
| Capital expenditure | 43 | 19 | 30 | 72 | 82 | 61 | 78 | 92 | 97 | 106 |
| Free cash flow | −48 | 36 | 46 | 44 | 215 | 445 | 429 | 887 | 920 | 1,059 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 63 | 146 | 684 | 869 |
| Acquisitions | 0 | 0 | 0 | 0 | 180 | 6 | 0 | 0 | 144 | 0 |
| Stock-based compensation | 35 | 30 | 411 | 206 | 287 | 408 | 539 | 617 | 610 | 622 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 191 | 257 | 769 | 656 | 774 | 803 | 1,032 | 1,046 | 964 | 866 |
| Debt incl. finance leases | — | 0 | 439 | 465 | 714 | 718 | 723 | 0 | 0 | 0 |
| Total assets | — | 620 | 1,615 | 1,891 | 2,336 | 2,541 | 3,013 | 2,971 | 4,013 | 4,230 |
| Total liabilities | — | 411 | 1,001 | 1,345 | 2,007 | 2,266 | 2,395 | 1,842 | 2,010 | 2,312 |
| Shareholders' equity | −347 | −339 | 614 | 546 | 326 | 276 | 617 | 1,130 | 2,003 | 1,918 |
| Margins and ratios | ||||||||||
| Gross margin | 73.1% | 77.2% | 72.5% | 75.0% | 75.0% | 77.9% | 78.7% | 79.3% | 79.1% | 79.4% |
| Operating margin | −30.4% | −10.0% | −60.8% | −19.9% | −12.0% | −2.9% | −3.5% | 1.1% | 6.7% | 9.3% |
| Net margin | −30.3% | −10.1% | −60.8% | −21.4% | −16.7% | −3.3% | −3.9% | 2.7% | 35.9% | 9.6% |
| Free cash flow margin | −12.6% | 7.0% | 6.5% | 4.5% | 14.8% | 21.1% | 17.1% | 32.1% | 30.9% | 32.9% |
| Return on capital | — | — | — | −47.8% | −44.2% | — | — | — | 35.6% | 25.4% |
| Return on equity | — | — | −309.4% | −35.9% | −55.8% | −23.3% | −21.8% | 8.5% | 68.2% | 15.8% |
| Return on assets | — | — | −38.2% | −11.9% | −11.5% | −2.9% | −3.5% | 2.5% | 30.6% | 7.5% |
| Net debt to EBITDA | — | — | — | — | — | −4.2x | — | −8.2x | −3.1x | −2.1x |